Jonathan Butterfield
About Jonathan Butterfield
Jonathan Butterfield is a Process Engineer III at Kite Pharma, where he has worked since 2020. He has a background in biochemistry from Hood College and has held various roles at Lonza, including Senior Manufacturing Project Specialist and Cell Therapy Supervisor.
Work at Kite Pharma
Jonathan Butterfield has been employed at Kite Pharma as a Process Engineer III since 2020. In this role, he is responsible for overseeing and improving manufacturing processes within the organization. Kite Pharma specializes in innovative cancer therapies, particularly in the field of cell therapy. Jonathan's expertise contributes to the development and optimization of these critical processes, ensuring efficiency and compliance with industry standards.
Previous Experience at Lonza
Before joining Kite Pharma, Jonathan Butterfield worked at Lonza Houston, Inc. as a Senior Manufacturing Project Specialist from 2019 to 2020. His role involved managing various manufacturing projects, focusing on enhancing production capabilities. Prior to this position, he served as a Cell Therapy Supervisor at Lonza from 2016 to 2019, where he supervised cell therapy operations. His career at Lonza began in 2012 as a Core Technician IV, where he gained foundational experience in manufacturing processes.
Education and Expertise
Jonathan Butterfield studied at Hood College, where he earned a degree in Biochemistry from 2008 to 2012. His educational background provides him with a strong foundation in biochemical processes, which is essential for his roles in the biotechnology and pharmaceutical industries. This expertise supports his work in process engineering and manufacturing, particularly in the development of biopharmaceutical products.
Background
Jonathan Butterfield has a diverse background in the biotechnology sector, with significant experience in manufacturing and process engineering. His career trajectory includes various roles at Lonza, where he developed skills in project management and supervision. His transition to Kite Pharma marks a continuation of his focus on innovative therapies, particularly in the area of cell therapy.